Michael Grunwald, MD

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD draw conclusions from two post hoc analyses of the REACH2 trial and share clinical pearls for community clinicians treating patients with acute Graft-Versus-Host Disease.

Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.

Two subject matter experts discuss a post hoc analysis of the REACH2 trial, focusing on the impact of cytopenias on treatment outcomes in patients with steroid-refractory acute Graft-Versus-Host Disease.

Drs Chao and Grunwald review available treatment options as informed by NCCN guidelines for patients with steroid-refractory acute Graft-Versus-Host Disease.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD introduce acute Graft-Versus-Host Disease (GvHD), sharing how it is diagnosed, how it differs from chronic GvHD, and common signs and symptoms.